Human Genome

Analyst calls Human Genome sell-off "overdone"
Analyst calls Human Genome sell-off "overdone"
MarketWatch
Human Genome
Flag link:
Top Biotech Takeout Targets in 2011
Top Biotech Takeout Targets in 2011
Minyanville
M&A
biotech
Biogen Idec
Human Genome
Seattle Genetics
GSK
Dendreon
Actelion
Biomarin
Exelixis
Vertex Pharmaceuticals
Celgene
Alexion
Shire
InterMune
Lexicon Pharmaceuticals
Savient
Merck KGaA
Flag link:
Biotech Stock Mailbag: Best Stocks to Watch in '11
Biotech Stock Mailbag: Best Stocks to Watch in '11
TheStreet.com
Oncothyreon
Xoma
Amarin
Opexa
Human Genome
Seattle Genetics
Vertex Pharmaceuticals
Merck
Dendreon
Biogen Idec
Amgen
Pharmasset
Flag link:
FDA's Top Q4 Blockbuster Drug Decisions
FDA's Top Q4 Blockbuster Drug Decisions
Fierce Biotech
Linjeta
Biodel
Afrezza
MannKind
FDA
Benlysta
Human Genome
GSK
Bydureon
Eli Lilly
Amylin
Alkermes
Brilinta
AstraZeneca
Pradaxa
Boehringer Ingelheim
Qnexa
Vivus
Contrave
Orexigen
ipilimumab
Bristol-Myers Squibb
Merck KGaA
cladribine
Flag link:
Novartis Halts Development of Two Drugs: Biotech's Latest Tribulations
Novartis Halts Development of Two Drugs: Biotech's Latest Tribulations
Seeking Alpha
Novartis
Actelion
AstraZeneca
Human Genome
JNJ
ONYX Pharmaceuticals
Pfizer
Rosetta Genomics
Targacept
Mycograb
albinterferon alfa-2b
Flag link:
21 Drugs Facing FDA Approval Decisions
21 Drugs Facing FDA Approval Decisions
TheStreet.com
FDA
Questcor Pharmaceuticals
Savient
Alkermes
Arena Pharmaceuticals
Roche
Novartis
Hospira
Human Genome
Alexza
Jazz Pharmaceuticals
Biodel
Amylin
Eli Lilly
Vivus
Avanir
Cadence Pharmaceuticals
Amgen
Cumberland
Orexigen
MannKind
Bristol-Myers Squibb
Flag link:
These Are the Top 10 Pharma Underperform Calls
These Are the Top 10 Pharma Underperform Calls
Motley Fool
Dendreon
Human Genome
Targacept
Vanda
Pharmacyclics
Acorda Therapeutics
MannKind
Flag link:
Human Genome Sciences signs supply deal for lupus drug Benlysta with Lonza
Human Genome Sciences signs supply deal for lupus drug Benlysta with Lonza
Yahoo/AP
Human Genome
partnerships
Lonza
Benlysta
Flag link:
14 Biotech Stocks Facing FDA Approval
14 Biotech Stocks Facing FDA Approval
TheStreet.com
Cell Therapeutics
Pozen
AstraZeneca
Dendreon
InterMune
Questcor Pharmaceuticals
Novartis
Biogen Idec
Teva Pharmaceuticals
Merck Serono
Savient
Javelin
Alexza
Human Genome
Jazz Pharmaceuticals
Arena Pharmaceuticals
Vivus
Biodel
Flag link:
2010 FDA Approvals Could Lead to Launch of Eight New Biotech Blockbusters
2010 FDA Approvals Could Lead to Launch of Eight New Biotech Blockbusters
BNET Pharma
FDA
Cadence Pharmaceuticals
Acorda Therapeutics
Auxilium
Gilead Sciences
Shire
Amylin
Cell Therapeutics
Dendreon
InterMune
Amgen
Human Genome
NicOx
Vivus
Arena Pharmaceuticals
Orexigen
Flag link:
Stocks to Watch at Biotech’s Bellwether Conference
Stocks to Watch at Biotech’s Bellwether Conference
Minyanville
Medtronic
Gilead Sciences
Human Genome
Novartis
GSK
Sangamo BioSciences
Indenix
Flag link:
Human Genome Faces Binary Event
Human Genome Faces Binary Event
Minyanville
Human Genome
Flag link:
Human Genome and Glaxo progress with lupus drug
Human Genome and Glaxo progress with lupus drug
Marketwatch
Human Genome
GSK
lupus
Benlysta
Flag link:
Human Genome shares fall on Lazard analyst outlook
Human Genome shares fall on Lazard analyst outlook
Yahoo/AP
Human Genome
lupus
Flag link: